Literature DB >> 8857955

The epitope specificity of heparin-induced thrombocytopenia.

P Horsewood1, T E Warkentin, C P Hayward, J G Kelton.   

Abstract

Heparin-induced thrombocytopenia (HIT) is caused by antibodies (HIT-Abs) that bind to a complex of heparin and platelet factor 4. We investigated the epitope specificity of the HIT-Abs, and found that the HIT-Abs recognized solid-phase immobilized complexes with an optimum ratio of four to eight molecules of PF4 per molecule of heparin. To try to define the epitopes within the PF4 molecule, intact and reduced (linearized) PF4 was tested against 29 different sera from patients with HIT. In addition, eight different peptides that spanned the PF4 molecule were studied for their ability to bind to the HIT-Abs either alone or in the presence of heparin. With the exception of a subpopulation of patient samples (5/29, 17%), we found that reduced PF4 and the peptides were uniformly non-reactive with the HIT-Abs in the presence of heparin. Reduced PF4 and PF4 carboxy-terminal peptides with a minimum size of 19 amino acids were recognized by a minority (5/29) of HIT-Abs samples but only when heparin was present. The specificity of this subgroup of samples from patients with HIT was highly restricted and the loss of one amino acid (peptide reduced in length from 19 to 18 amino acids) rendered the peptides non-reactive. The clinical characteristics of these patients were similar to the other HIT patients. These studies demonstrate that the majority of HIT-Abs recognize a noncontiguous conformational epitope on the PF4 molecule that is produced when four to eight PF4 molecules are bound together by heparin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8857955     DOI: 10.1046/j.1365-2141.1996.d01-1876.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  Laboratory testing for heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

2.  Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis.

Authors:  Yvette C Tanhehco; Ann H Rux; Bruce S Sachais
Journal:  Transfusion       Date:  2010-10-26       Impact factor: 3.157

3.  Eptifibatide-induced thrombocytopenia and thrombosis.

Authors:  Slava Epelman; Deepu Nair; Ross Downey; Mike Militello; Arman T Askari
Journal:  J Thromb Thrombolysis       Date:  2006-10       Impact factor: 2.300

Review 4.  Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management.

Authors:  T E Warkentin
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

5.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

Review 6.  Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results.

Authors:  Gowthami M Arepally; Marcie J Hursting
Journal:  J Thromb Thrombolysis       Date:  2008-03-28       Impact factor: 2.300

7.  Investigation of a potential protective mechanism against heparin-induced thrombocytopenia in patients on chronic intermittent hemodialysis.

Authors:  Yvette C Tanhehco; Adam Cuker; Michael Rudnick; Bruce S Sachais
Journal:  Thromb Res       Date:  2013-01-08       Impact factor: 3.944

8.  [Heparin-induced thrombocytopenia with unfractionated heparin. A prospective study of inpatient treatment of internal medicine patients].

Authors:  H Heidrich; K Kahl; C Penninger; B Bechstein; M Birkenmaier; S Dressler; C Fahrig; J Helmis; G Herman; U von Knobloch; M Ladleif; K Meier; M Rudolph; B Schlich; M Wanke; B Zwernemann
Journal:  Med Klin (Munich)       Date:  1998-06-15

9.  Heparin-induced thrombocytopaenia (HIT)-an overview: what does the nephrologist need to know and do?

Authors:  Tina Dutt; Michael Schulz
Journal:  Clin Kidney J       Date:  2013-12

10.  Update on the safety and bioequivalence of biosimilars - focus on enoxaparin.

Authors:  Walter Jeske; Jeanine M Walenga; Debra Hoppensteadt; Jawed Fareed
Journal:  Drug Healthc Patient Saf       Date:  2013-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.